限制淋巴瘤缓解期患者的监测影像检查:一项混合方法研究促成「明智选择」推荐
该混合方法研究分析了淋巴瘤缓解期监测FDG-PET/CT的性能、假阳性率、临床后果与费用,并访谈了26例患者和11名临床医生。假阳性率按扫描计为25.1%(95%CI 20.5-30.5),按患者计为41.7%(95%CI 37.9-45.6),每检出1例复发的估计费用为50 000美元。研究认为定量数据结合定性态度资料可增强对限制过度监测影像的「明智选择」推荐的接受度。
要点
- 淋巴瘤缓解期监测FDG-PET/CT假阳性率高,导致频繁额外检查。
- 假阳性率受所见特征和部位影响,按扫描和按患者统计的假阳性率不同。
- 患者通过监测影像寻求安心但感到有压力,临床医生常感患者施压要求开检查。
核心结论
- 定量展示监测影像的后果与费用,并补充患者和医生态度资料,可能增强对限制过度使用的「明智选择」推荐的接受度。
研究设计与样本
- 混合方法研究,分析两个淋巴瘤患者队列的监测FDG-PET/CT结果,队列1为215例霍奇金和非霍奇金淋巴瘤,队列2为203例霍奇金淋巴瘤。
- 假阳性通过活检阴性或临床随访定义。
- 定性部分采用焦点小组讨论和深度访谈,分别收集26例患者和11名临床医生的态度。
关键影像表现/征象
- 假阳性率在队列1按扫描计为25.1%(95%CI 20.5-30.5),在队列2按患者计为41.7%(95%CI 37.9-45.6)。
- 所见的特定特征和部位会改变假阳性率。
- 队列2每检出1例复发的估计费用为50 000美元。
临床应用与阅片要点
- 临床医生常感患者压力而开具监测影像,但普遍认为监测影像不影响预后(有重要例外)。
- 患者对治疗医生的信任是接受放弃影像检查的重要因素。
- 临床医生欢迎专业指南,但拒绝对其使用的监管限制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Under the 'Choosing Wisely' (CW) framework, professional organisations internationally have advocated limiting imaging for asymptomatic patients following curative cancer therapy, based on limited value and high cost. F18-fluorodeoxyglucose (FDG) positron emission tomography-CT (PET/CT) was widely adopted locally for surveillance lymphoma imaging after 2004.
OBJECTIVES: Prior to ratification of a local CW recommendation to limit surveillance imaging in lymphoma, we aimed to assess: (A) performance characteristics of surveillance FDG-PET/CT; (B) rates, clinical consequences and costs of false positives (FP); and (C) patients and professionals' attitudes towards overuse.
METHODS: Mixed methods (quantitative and qualitative) study. We analysed surveillance FDG-PET/CT results of two patient cohorts (n1=215 Hodgkin lymphoma and non-Hodgkin lymphoma; n2=203 Hodgkin lymphoma only). FPs were defined by negative biopsy or clinical follow-up. We held focus group discussions and in-depth interviews eliciting attitudes of 26 patients and 11 clinicians, respectively.
RESULTS: FPs were observed in 25.1% (95% CI 20.5 to 30.5) per scan-cohort 1, and 41.7% (95% CI 37.9 to 45.6) per patient-cohort 2, engendering frequent additional testing. Specific characteristics and location of findings altered the FP rate. The estimated cost per relapse detected was $50 000 (cohort 2). Patients sought reassurance via surveillance imaging, which they considered highly accurate, yet stressful. Aware of radiation risks, they were largely unconcerned about consequences of FPs. Confidence in the treating physicians was an important factor in patients' acceptance of forgoing imaging. Clinicians, frequently under patient pressure to order imaging, generally believed that it did not affect prognosis (with important exceptions), welcomed professional guidelines, but rejected regulatory restrictions on its use.
CONCLUSION: Acceptance of CW recommendations to limit overuse may be enhanced by quantitative data on consequences and costs of surveillance imaging, supplemented by qualitative data on patient and physician attitudes.
引用
- Paltiel O, Raviv Sharabi G, Tzemach R, et al. Limiting surveillance imaging for patients with lymphoma in remission: a mixed methods study leading to a Choosing Wisely recommendation. BMJ Qual Saf. 2020. PMID: 32467340. doi:10.1136/bmjqs-2019-010756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。